Pliant Therapeutics Shares it 52-Week Low
Pliant Therapeutics ends its Phase 2b IPF trial for bexotegrast, prompting a Needham downgrade to Hold due to limited ...
Hosted on MSN3h
Leerink Partners Downgrades Pliant Therapeutics (PLRX)Fintel reports that on March 3, 2025, Leerink Partners downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from ...
Citi lowered the firm’s price target on Pliant Therapeutics (PLRX) to $1.50 from $4 and keeps a Neutral rating on the shares. The company ...
Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The ...
Pliant Therapeutics shares were halted in early morning trading after falling 25% to $2.57, after the company said it is discontinuing a phase 2b trial for bexotegrast in patients with idiopathic ...
NEW YORK CITY, NY / ACCESS Newswire / February 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) is anticipated to issue its quarterly earnings data before the market ...
A clinical study testing a Pliant Therapeutics drug once considered a promising prospect for treating a fatal lung disorder is now on pause at the recommendation of independent outside observers.
https://www.tipranks.com/news/the-fly/travere-therapeutics-price-target-raised-to-30-from-24-at-td-cowen JPMorgan downgraded Pliant Therapeutics (PLRX) to Neutral ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pliant Therapeutics (PLRX – Research Report) and Capricor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback